Clinical trial
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With…
NCT00399659 · Novartis, Industry · Terminated
Key facts
| NCT number | NCT00399659 |
|---|---|
| Title | Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain. |
| Official title | A 52-week Extension to Study CHTF919N2201 to Evaluate the Safety and Efficacy of Tegaserod (6 mg b.i.d. and 12 mg o.d.) Given Orally for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain |
| Lead sponsor | Novartis, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Opioid-induced Constipation |
| Intervention type | Drug |
| Interventions | Tegaserod |
| Enrollment | 360 |
| Start date | Nov 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Nov 15, 2006 |
| Last update posted | May 1, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: